Actemra 162mg (SC) (Tocilizumab)

Actemra is a first-in-class anti-IL-6 receptor (aIL-6R) therapy. IL-6 is believed to play a key role in activating the inflammatory pathway that contributes to the signs and symptoms of RA and other inflammatory autoimmune conditions. Actemra binds to IL-6 receptors, blocking the pro-inflammatory effect of IL-6 cytokines.

Actemra is approved for the treatment of rheumatoid arthritis (RA), pediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis (GCA), CAR-T cell-induced cytokine release syndrome (CRS), and certain hospitalized adult patients with coronavirus disease 2019 (COVID-19). 

Actemra is available in both subcutaneous (SC) and intravenous (IV) formulations.

Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]